Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Genelux Corporation
Genelux Corporation
GOG Foundation
pharmaand GmbH
Shandong University
AGO Research GmbH
Canadian Cancer Trials Group
Swiss Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GOG Foundation
GOG Foundation
European Organisation for Research and Treatment of Cancer - EORTC